NTpharma LLCNTpharma LLC

Production of vaccines and biopharmaceuticals based on pseudoadenoviral nanoparticles and special nanostructuresProduction of vaccines and biopharmaceuticals based on pseudoadenoviral nanoparticles and special nanostructures

Scientific groups providing the project implementation

Maxim Shmarov, Doctor of Biological Sciences, is currently preparing to defend his thesis for the degree of Doctor of Biological Sciences. Maxim leads a team of 6 scientists.

The main field of research conducted by Maxim Shmarov is development of recombinant psevdoadenoviral nanoparticles production technology and creation of preventive and therapeutic drugs (vaccines, immunomodulators, gene therapies) on their basis.

The following results have been achieved with the direct involvement of M. Shmarov:

  • An original technology of production of pseudoadenoviral nanoparticles capable of delivering a variety of genes of therapeutic intervention in the target cell.
  • A series of candidate marked vector vaccines of new generation against avian viruses and rabies which are characterized by high protective effect.

Maxim Shmarov participated in preparation of 6 draft methodological recommendations and 3 draft guidelines which were approved by Gennady Onishchenko, Chief Sanitary Official of the Russian Federation.

Maxim Shmarov actively participates in scientific conferences, supervises postgraduate students, conducts educational courses. Maxim Shmarov has 63 publications and 4 patents.

Irina Tutykhina, Candidate of Biological Sciences. Since 2009 Irina Tutyhina has been in charge of a research group including 2 researchers and 2 postgraduate students. Irina is an autonomous researcher and a highly qualified expert in the field of molecular biotechnology, virology and immunology.

The main field of research conducted by Irina is development of recombinant pseudoadenoviral nanoparticles production technology, creation of prophylactic and therapeutic drugs (vaccines, immunomodulators, gene therapies) on their basis and optimization of technology of recombinant pseudoadenoviral nanoparticles growing in wave-type bioreactors.

The following results have been achieved with the direct involvement of I. Tutykhina :

  • An original technology of production of pseudoadenoviral nanoparticles capable to deliver a variety of genes of therapeutic intervention in the target cell.
  • A series of candidate marked vector vaccines of new generation against bird viruses and rabies which are characterized by high protective effect.
  • An efficient system of recombinant human lactoferrin protein expression in eukaryotic cells.

Irina Tutykhina participated in preparation of 5 draft methodological recommendations and 3 draft guidelines which were approved by Gennady Onishchenko, Chief Sanitary Official of the Russian Federation.

Irina has 17 publications and 4 patents.

Map

Close window

Map

Close window